To dissect the potential of NASH development associated with natural aging and to address the feasibility of controlling this pathology via targeting senescent cells, we examined a subgroup of mice at 20 months of age, and administered them with a vehicle, PDK4-IN or PCC1 for 4 months. This evidence concerns the gene PDK4 and metabolic dysfunction-associated steatohepatitis.